Clinical trials for Colon cancer

172 currently recruiting clinical trials
Phase 1 Colon cancer Rectal cancer Pancreas cancer #NCT07094113
Partie 3b: Exploration et expansion des doses en thérapie combinée CCR et PDAC
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other KRAS KRAS G12C KRAS non G12C KRAS G12D
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Amgen
Phase 1 Colon cancer Rectal cancer #NCT06625775 #2024-519445-29-00
Cohortes Cancer colorectal KRAS muté
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other KRAS KRAS G12C KRAS non G12C KRAS G12D
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
BRAF HER2 MSI/dMMR
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06561685
Phase 1a Escalade de dose
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
SMARCA4
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Eli Lilly et compagnie
Phase 1 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06561685
Phase 1b Extension Partie B
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
SMARCA4
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Eli Lilly et compagnie
Phase 1 Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05495295 #2021-004170-55
Cohorte d'expansion 3 (Tumeurs sélectionnées)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Phost'In Therapeutics
Phase 1 Lung cancer Colon cancer Rectal cancer Kidney cancer #NCT05433142
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Clear cell carcinoma Papillary carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
2 recruiting sites
Xencor, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05836324 #2022-502456-31-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Incyte Corporation
Phase 1 Lung cancer Colon cancer Rectal cancer Pancreas cancer Stomach and esophageal cancer #NCT06131840
Partie C
Required histologic types
SCLC (Small Cell Lung Cancer) NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1 2 3 or more
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
1 recruiting site
Seagen
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04617522 #2022-501508-82-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Gilead Sciences
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05614739
Cohortes A1 et C1
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Eli Lilly et compagnie